CAPTRUST Financial Advisors
STOK icon

CAPTRUST Financial Advisors’s Stoke Therapeutics STOK Stock Holding History

CAPTRUST Financial Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-68
Closed -$1K – 5133
2022
Q1 		$1K Buy
+68
New +$1.36K ﹤0.01% 4750

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CAPTRUST Financial Advisors's STOK Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of Stoke Therapeutics (STOK) in Q2 2022, closing a stake of 68 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in STOK in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 92 funds tracked by Wall St. Rank hold STOK as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining Stoke Therapeutics position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 68 Stoke Therapeutics shares in Q2 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Stoke Therapeutics in Q1 2022 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Stoke Therapeutics position peaked at $1K in Q1 2022.
  • 92 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.